CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114 RESPONSE

被引：2

作者：

Ferrannini, Ele ^{[1
]}

Mark, Michael ^{[2
]}

Mayoux, Eric ^{[2
]}

机构：

[1] CNR, Inst Clin Physiol, Pisa, Italy

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Cardiometab Dis Res, Biberach, Germany

来源：

DIABETES CARE | 2016年 / 39卷 / 12期

关键词：

D O I：

10.2337/dci16-0033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E226 / E226

页数：1

共 6 条

[1] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114
Jordan, Jens
El-Armouche, Ali
Hanefeld, Markolf
Bornstein, Stefan R.
Birkenfeld, Andreas L.
DIABETES CARE, 2016, 39 (12) : E224 - E225
[2] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
Ferrannini, Ele
Mark, Michael
Mayoux, Eric
DIABETES CARE, 2016, 39 (07) : 1108 - 1114
[3] Response to Comment on Ferrannini et al. Diabetes Care 2016;39:1108-1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115-1122
Ferrannini, Ele
Mark, Michael
Mayoux, Eric
DIABETES CARE, 2016, 39 (11) : E196 - E197
[4] The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015 RESPONSE
Neeland, Ian J.
Kasai, Takatoshi
Inzucchi, Silvio E.
Wojeck, Brian S.
Yaggi, Henry K.
Johansen, Odd Erik
DIABETES CARE, 2021, 44 (06) : E137 - E138
[5] The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015
Brikman, Shay
Dori, Guy
DIABETES CARE, 2021, 44 (06) : E136 - E136
[6] Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831 RESPONSE
Kaul, Sanjay
DIABETES CARE, 2017, 40 (12) : E175 - E176

← 1 →